RayKnowChina Research Map
Shortlist0

RecruitingStomach cancerPhase 1

Registered title, quoted from ClinicalTrials.gov

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

An open trial on stomach cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 2

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study sitePeking Union Medical College Hospital北京协和医院BeijingHospital page
  2. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07114601, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Must have histologically or cytologically proven diagnosis of locally advanced, unresectable, or metastatic cancer.

    Inclusion criterion 1

    Must have the following histologically or cytologically confirmed diagnosis:

    Inclusion criterion 6

    For participants with breast cancer diagnosis, where possible, ER and HER2 status should be assessed from the most recent tissue biopsy taken at the time of presentation with recurrent or metastatic disease.

    Inclusion criterion 16

    To fulfill the requirement for ER+ disease by local testing, a tumor must express the ER immunohistochemistry, as defined in the relevant American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.

    Inclusion criterion 17

  3. Phase 1a (Cohort A1 and A2) only: Previously received radiopharmaceutical or radioligand therapy. For participants with prostate cancer, prior ¹⁷⁷Lu-prostate-specific membrane antigen (PSMA) is permitted.

    Exclusion criterion 1

    Previously received any prior hemi-body or whole-body radiotherapy, or prior external beam radiation therapy (EBRT) to greater than 25% of the bone marrow.

    Exclusion criterion 3

  4. Must have an Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 1.

    Inclusion criterion 19

  5. Must be assessed by computed tomography (CT)/magnetic resonance imaging (MRI) to confirm at least 1 of the following:

    Inclusion criterion 2

    At least 1 measurable target lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Inclusion criterion 3

    If only bone lesions are present without a soft-tissue component, a bone scan or MRI must confirm at least 2 detectable lesions considered to represent active metastases

    Inclusion criterion 4

  6. Have known active hepatitis B virus (HBV). Exception: Individuals with chronic HBV if they:

    Exclusion criterion 6

    Have undetectable HBV DNA ≤14 days of C1D1.

    Exclusion criterion 10

    Have known active hepatitis C virus (HCV). Exception: Individuals previously treated for HCV if they:

    Exclusion criterion 11

    Have an HCV viral load below the limit of quantification ≤14 days of C1D1 and.

    Exclusion criterion 13

    Are positive for anti-HCV antibodies and negative for HCV ribonucleic acid (RNA) before randomization.

    Exclusion criterion 14

    Have untreated human immunodeficiency virus (HIV) infection. Exception: Individuals who have well-controlled HIV infection/disease and they:

    Exclusion criterion 15

    Has an active second malignancy unless in remission with life expectancy greater than 2 years.

    Exclusion criterion 20

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07114601, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Must have histologically or cytologically proven diagnosis of locally advanced, unresectable, or metastatic cancer.
  • Must be assessed by computed tomography (CT)/magnetic resonance imaging (MRI) to confirm at least 1 of the following:
  • At least 1 measurable target lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  • If only bone lesions are present without a soft-tissue component, a bone scan or MRI must confirm at least 2 detectable lesions considered to represent active metastases
  • Must have GRPR-positive disease, defined by investigator assessment of GRPR imaging.
  • Must have the following histologically or cytologically confirmed diagnosis:
  • Estrogen receptor (ER+)/human epidermal growth factor receptor 2 (HER2-) breast cancer
  • ER+/HER2+ breast cancer
  • Esophageal squamous cell carcinoma
  • Adenocarcinoma of the stomach, gastroesophageal junction, or esophagus
  • Colorectal carcinoma
  • Metastatic castration-resistant prostate cancer
  • Endometrial carcinoma. Carcinosarcoma is eligible. Uterine leiomyosarcoma, adenosarcoma, or endometrial stromal sarcoma is not eligible.
  • Low-grade papillary serous ovarian cancer
  • Other non-Central Nervous System (CNS) primary GRPR-positive solid tumors (Cohorts A1 dose escalation and D1 dose expansion only)
  • For participants with breast cancer diagnosis, where possible, ER and HER2 status should be assessed from the most recent tissue biopsy taken at the time of presentation with recurrent or metastatic disease.
  • To fulfill the requirement for ER+ disease by local testing, a tumor must express the ER immunohistochemistry, as defined in the relevant American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.
  • HER2 status should be determined by local testing, as defined in the relevant ASCO/CAP Guidelines.
  • Must have an Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 1.
  • Must be able to comply with outpatient treatment, laboratory monitoring, imaging, and required clinic visits for the duration of trial participation.

Exclusion Criteria:

  • Phase 1a (Cohort A1 and A2) only: Previously received radiopharmaceutical or radioligand therapy. For participants with prostate cancer, prior ¹⁷⁷Lu-prostate-specific membrane antigen (PSMA) is permitted.
  • Has a history of ongoing acute pancreatitis within 1 year of screening.
  • Previously received any prior hemi-body or whole-body radiotherapy, or prior external beam radiation therapy (EBRT) to greater than 25% of the bone marrow.
  • A bone superscan, defined as a bone scan that demonstrates markedly increased skeletal radioisotope uptake relative to soft tissues in association with absent or faint genitourinary tract activity.
  • Has evidence of ongoing and untreated urinary tract obstruction or unmanageable urinary incontinence.
  • Have known active hepatitis B virus (HBV). Exception: Individuals with chronic HBV if they:
  • Have positive HBsAg
  • Are on suppressive antiviral therapy, as allowed per local regulations prior to C1D1
  • Remain on the same antiviral treatment throughout study, and should follow local standards for continuation of therapy after completion of trial therapy.
  • Have undetectable HBV DNA ≤14 days of C1D1.
  • Have known active hepatitis C virus (HCV). Exception: Individuals previously treated for HCV if they:
  • Completed curative antiviral therapy.
  • Have an HCV viral load below the limit of quantification ≤14 days of C1D1 and.
  • Are positive for anti-HCV antibodies and negative for HCV ribonucleic acid (RNA) before randomization.
  • Have untreated human immunodeficiency virus (HIV) infection. Exception: Individuals who have well-controlled HIV infection/disease and they:
  • Are on a stable and permitted antiretroviral therapy (ART) regimen without changes in drug or dose, for at least 4 weeks prior to C1D1
  • Have a viral load of <400 copies/mL ≤14 days of C1D1.
  • Have a CD4+ T-cell count ≥350 cells/mL ≤14 days of C1D1.
  • Have not had an opportunistic infection within the past 12 months.
  • Has an active second malignancy unless in remission with life expectancy greater than 2 years.
  • Has known hypersensitivity to any component or excipient of LY4257496.

Quoted from ClinicalTrials.gov, NCT07114601, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07114601, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07114601